HIV Drugs

Decision Resources forecasts that the HIV drug market will grow to more than $8 billion by 2013. Novel therapeutic classes that augment treatment options for the treatment-experienced population will drive the market.
The new Pharmacor study entitled Human Immunodeficiency Virus finds that, despite advances in therapy, the HIV drug market is constrained by social and political pressures on the pharmaceutical industry.
"HIV is a highly politically and socially charged disease, this factor has important implications for drug developers," said Aarti Raja, Ph.D., analyst, Decision Resources. "Pharmaceutical manufacturers have been under increasing public pressure to address the global HIV crisis by drastically reducing drug prices for developing countries. Beyond the profitability concerns directly related to the developing world, manufacturers worry that the high price differentials created by such a move may increase price pressure in the major markets."
Since its identification in the early 1980s, HIV has become one of the most serious epidemics of modern times and a significant source of morbidity, mortality, and cost to society. Beginning in the late 1980s, advances in the understanding and treatment of HIV, particularly the development of highly active antiretroviral therapy (HAART), have substantially halted the progression of HIV and reduced mortality from AIDS.
Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.
Decision Resources provides research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
View the original article here